FOCL Stock Forecast & Price Target

Edap TMS is in a favorable financial position, with a successful capital raise of over $42 million and a net cash position of approximately $24.9 million, which will be used to accelerate commercial growth, fund expansion into new indications, and advance new technologies. The company's performance in the second quarter of 2026 has shown strong procedure volume growth and a narrowing gap between procedure growth and treatment-driven revenue, indicating increasing demand for their flagship platform, Focal One Robotic HIFU. In addition, the recent rebranding to FocalTherics and the focus on the core HIFU business show a clear strategy and path to profitability. The endorsements from key opinion leaders and plans to invest in next-generation imaging and AI, as well as expand into histotripsy, demonstrate the company's dedication to staying at the forefront of the industry and differentiating themselves from competitors.

Edap TMS is currently developing technology for the treatment of BPH and endometriosis in addition to its current focus on prostate cancer. However, these indications are still in early commercial stages and the US regulatory strategy is not expected to be finalized until the end of 2026. While management expects these indications to contribute around 10%–15% of the 2028 topline targets, prostate cancer will remain the primary growth driver. Without significant data or commercial success in these new indications, we remain skeptical of their potential impact on the company's overall financials.